Key clinical point: Vemurafenib has durable antitumor activity in patients with BRAF V600–mutant NSCLC.
Major finding: The objective response rate was 37.1% overall (37.5% in previously untreated patients and 37.0% in previously treated patients).
Study details: Phase 2 open-label, single-arm, multicohort trial with analysis of 62 patients having BRAF V600–mutant NSCLC (VE-BASKET trial).
Disclosures: Dr. Subbiah disclosed having a consulting or advisory role with or receiving research funding from numerous pharmaceutical companies. The study was sponsored by Hoffmann–La Roche.
Subbiah V et al. JCO Precis Oncol. 2019 June 27. doi: 10.1200/PO.18.00266.